Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

{
  "signal_id": "016cd4cc-2df7-cc08-ecc3-dff0e2371036",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-01T20:45:00+00:00",
  "company": {
    "name": "Abbott",
    "domain": "abbott.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/abbotts-tectonic-clinical-trial-demonstrates-strong-30-day-outcomes-and-high-procedural-success-for-its-investigational-sonicforce-coronary-intravascular-lithotripsy-system-302925602.html",
    "title": "Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System",
    "ticker": "NYSE:ABT",
    "excerpt": "ABBOTT PARK, Ill. , Nov. 1, 2026 /PRNewswire/ -- Abbott (NYSE: ABT ), the global healthcare leader, announced strong 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular Lithotripsy (IVL) Investigational Device Exemption (IDE) Study evaluating the use of its investigational SonicForce TM Coronary IVL System, which is designed to crack calcium buildup in coronary arteries. The study met its primary safety and effectiveness endpoints, demonstrating excellent early clinical outcomes in patients with severe coronary calcification. Results from the TECTONIC CAD IVL IDE Study were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego (Oct. 31-Nov. 3, 2026) and simultaneously published in the Journal of the American College of Cardiology: Cardiovascular Interventions . The TECTONIC study enrolled 335 patients with severely calcified CAD across 40 U.S. sites and evaluated the investigational SonicForce Coronary IVL System in people with narrowed coronary arteries caused by calcium buildup. Key data from the trial include: IVL is a minimally invasive medical procedure that uses acoustic pressure waves, similar to technology used for kidney stones, to crack hard plaque in narrowed heart vessels. In a prespecified imaging sub-study of 106 patients, optical coherence tomography (OCT) imaging identified calcium fractures...",
    "product": "SonicForce Coronary IVL System",
    "summary": "Abbott announced positive 30-day clinical trial results from the TECTONIC IDE study evaluating its investigational SonicForce Coronary Intravascular Lithotripsy System.",
    "location": "Abbott Park, Illinois, United States",
    "planning": false,
    "image_url": "https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "SonicForce Coronary IVL System",
      "full_text": "investigational SonicForce TM Coronary IVL System",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-11-01T20:45:00Z",
    "location_data": [
      {
        "city": "Abbott Park",
        "state": "Illinois",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Abbott (NYSE: ABT ), the global healthcare leader, announced strong 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular Lithotripsy (IVL) Investigational Device Exemption (IDE) Study evaluating the use of its investigational SonicForce TM Coronary IVL System, which is designed to crack calcium buildup in coronary arteries."
  }
}

curl https://signals.autobound.ai/v1/signals/016cd4cc-2df7-cc08-ecc3-dff0e2371036 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbott.com","limit":20}'